IGF-1 LR3 (1MG)

Additional Info

Properties

• IGF-1 LR3 Chemical Formula: C400H625N111O115S9
• IGF-1 LR3 Molecular Weight: 9117.60 g/mol
• IGF-1 LR3 Sequence: MFPAMPLSSL FVNGPRTLCG AELVDALQFV CGDRGFYFNK PTGYGSSSRR APQTGIVDEC CFRSCDLRRL EMYCAPLKPA KSA
• Total Amount: 1mg (1 vial)
• Shelf Life: 36 months

Shipping

Available to USA and Canada. For international orders, if your shipment is seized, contact us for a 50% discount applicable on your next purchase.

Disclaimer

The information provided does not replace medical advice, diagnosis, or treatment. Consult your physician or qualified healthcare provider for any medical concerns. Never delay seeking medical advice based on information seen or read here. We assume no responsibility or liability for the use of our research compounds and products. Please note they are sold exclusively for research purposes and are not intended for personal use.

Additional Label & Product Information

Important Caution:

These chemicals are intended solely for research or laboratory use and are not approved by the FDA for human consumption.

Usage Instructions:

Avoid contact with skin and eyes. In case of contact, rinse thoroughly with water. Seek medical assistance if feeling unwell or in case of accidental ingestion. Store the lyophilized (freeze-dried) peptide at room temperature immediately upon receipt and avoid frequent freeze-thaw cycles to maintain peptide stability.

Product Disclaimer:

This product is not meant to diagnose, treat, cure, or prevent any disease. Administer only as specified by your specific research or laboratory protocol.

Resources

1. Assefa B, Mahmoud AM, Pfeiffer AFH, Birkenfeld AL, Spranger J, Arafat AM. The journal Oxidative Medicine and Cellular Longevity published a study in 2017 that explored the role of Insulin-Like Growth Factor (IGF) Binding Protein-2 in inducing GLUT-4 translocation and enhancing glucose uptake independently of IGF-1 in 3T3-L1 adipocytes (PMID: 29422987; PMCID: PMC5750484).
2. Tomas FM, Knowles SE, Owens PC, Chandler CS, Francis GL, Read LC, Ballard FJ. In a study published in the Biochemical Journal in 1992, researchers investigated the anabolic effects of Insulin-Like Growth Factor-I (IGF-I) and its variants in dexamethasone-treated rats (PMID: 1371669; PMCID: PMC1130894).
3. Li N, Yang Q, Walker RG, Thompson TB, Du M, Rodgers BD. Endocrinology published research in 2016 examining how Myostatin attenuation in vivo reduces adiposity while activating adipogenesis (PMID: 26580671; PMCID: PMC4701895).
4. Bailes J, Soloviev M. The journal Biomolecules in 2021 discussed the role of Insulin-Like Growth Factor-1 (IGF-1) and its monitoring in medical diagnostics and sports (PMID: 33557137; PMCID: PMC7913862).
5. AsghariHanjani N, Vafa M. The Medical Journal of the Islamic Republic of Iran published an article in 2019 reviewing the involvement of IGF-1 in obesity, cardiovascular disease, and cancer (PMID: 31456980; PMCID: PMC6708115).
6. Philippou A, Barton ER. Growth Hormone & IGF Research published a review in 2014 optimizing IGF-I for skeletal muscle therapeutics (PMID: 25002025; PMCID: PMC4665094).